Huadong Medicine Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Huadong Medicine Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Huadong Medicine Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Huadong Medicine Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Huadong Medicine Co Ltd (Huadong Medicine) is a pharmaceutical company that specializes in the production and sales of antibiotics, Chinese patent medicines, synthetic drugs, and genetic engineering drugs. It also carries out the wholesale business of Chinese and Western medicine, Chinese herbal medicines, medical apparatus and instruments. Huadong Medicine's product pipeline includes Bailing Capsule, Sirolimus Oral Solution, Tacrolimus Capsules, Mycophenolate mofetil Dispersible Tablets, New Cyclosporin Soft Capsules, Metformin, Pioglitazone Hydrochloride Tablets, Acarbose Tablets, and Indobufen Tablets, among others. Its major product pipelines are mainly in the fields of transplant immunity, endocrinology, cardiovascular system, and the digestive system. The company also carries out research and development across various areas, such as diabetes, oncology, the autoimmune field, and others. Huadong Medicine is headquartered in Hangzhou, Zhejiang, China.
Headquarters
China
Address
Huadong Medicine New Office Building, No. 866 Moganshan Road, Hangzhou, Zhejiang, 310011
Website
www.eastchinapharm.com
Telephone
86 571 89903388
No of Employees
19,095
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
000963 (SHE)
Revenue (2024)
$6.1B
4.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-2.8%
(2024 vs 2023)
Market Cap*
$7.9B
Net Profit Margin (2024)
XYZ
-6.6%
(2024 vs 2023)
* As of and is in US$
Huadong Medicine Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Immunosuppressive Agents | Glacial Spa |
| Endocrine Drugs | |
| Digestive System Drugs | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In December, Hangzhou Sino-US Huadong Medicine Co., Ltd. signed an agreement with SynerK PharmaTech (Suzhou) Co., Ltd. to jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen to treat hypertension. |
| 2023 | Contracts/Agreements | In December, the company announced a collaboration with Impact Therapeutics for the promotion of Senaparib in China. |
| 2023 | Contracts/Agreements | In October, Huadong Medicine Aesthetics Investment (Hongkong) and ATGC Co entered into a strategic collaboration and licensing agreement under which Sinclair granted a global exclusive license to develop and commercialize ATGC’s botulinum toxin product, ATGC-110 for all aesthetic and therapeutic indications. |
Competitor Comparison
| Key Parameters | Huadong Medicine Co Ltd | Jointown Pharmaceutical Group Co Ltd | Cachet Pharmaceutical Co Ltd | Simcere Pharmaceutical Group Ltd | Shenzhen Salubris Pharmaceuticals Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Hangzhou | Wuhan | Beijing | Nanjing | Shenzhen |
| State/Province | Zhejiang | Hubei | Beijing | Jiangsu | Guangdong |
| No. of Employees | 19,095 | 29,862 | 1,741 | 7,038 | 4,087 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Luliang | General Manager; Chairman | Executive Board | 2021 | 52 |
| Qiu Renbo | Chief Financial Officer | Senior Management | 2019 | 44 |
| Zhang Jianfei | Deputy General Manager | Senior Management | 2022 | 51 |
| Zhang Zhongxing | Deputy General Manager | Senior Management | 2025 | 54 |
| Wu Hui | Deputy General Manager | Senior Management | 2019 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer